Literature DB >> 12619927

Abnormal regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in X-linked hypophosphatemia: a translational or post-translational defect.

Ikuma Fujiwara1, Rolands Aravindan, Ron L Horst, Marc K Drezner.   

Abstract

The hyp mouse exhibits abnormal metabolic/hormonal regulation of renal 25(OH)D-1alpha-hydroxylase activity. Whether this results from aberrant transcriptional regulation of the 1alpha-hydroxylase gene, CYP27B1, remains unknown. To investigate this possibility, we compared phosphate and parathyroid hormone effects on renal proximal convoluted tubule and thyrocalcitonin effects on proximal straight tubule enzyme activity and mRNA expression in normal and hyp mice. We assayed 25(OH)D-1alpha-hydroxylase activity by measuring 1,25(OH)2D production and mRNA by ribonuclease protection. Phosphate-depleted mice exhibited a 3-fold increment of 25(OH)D-1alpha-hydroxylase activity compared with normals, whereas hyp mice displayed no enhanced enzyme function. Phosphate-depleted mice concurrently displayed a 2-fold increase in mRNA transcripts; in contrast, despite failure to alter enzyme activity, hyp mice exhibited a similar increment in mRNA transcripts. Parathyroid hormone stimulation of normal mice increased 25(OH)D-1alpha-hydroxylase activity 10-fold, while eliciting only a 2-fold increment in hyp mouse enzyme function. This disparity occurred despite increments of mRNA transcripts to comparable levels (22.2 +/- 3.5- vs. 19.9 +/- 1.8-fold). The dissociation between phosphate- and parathyroid hormone-mediated transcriptional activity and protein function was not universal. Thus, thyrocalcitonin stimulation of normal and hyp mice resulted in comparable enhancement of mRNA transcripts and enzyme activity. These observations indicate that abnormal regulation of vitamin D metabolism in hyp mice occurs in the proximal convoluted tubule and results, not from aberrant transcriptional regulation, but from a defect in translational or post-translational activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619927     DOI: 10.1359/jbmr.2003.18.3.434

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

2.  CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders.

Authors:  Xiuying Bai; Dengshun Miao; Sophia Xiao; Dinghong Qiu; René St-Arnaud; Martin Petkovich; Ajay Gupta; David Goltzman; Andrew C Karaplis
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

Review 3.  Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule.

Authors:  Kennedi Young; Megan R Beggs; Chelsey Grimbly; R Todd Alexander
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-28

Review 4.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

5.  Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  Bone       Date:  2015-06-04       Impact factor: 4.398

6.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

7.  Dietary vitamin D3 deprivation suppresses fibroblast growth factor 23 signals by reducing serum phosphorus levels in laying hens.

Authors:  Jiakun Yan; Chong Pan; Yanli Liu; Xujie Liao; Jionghao Chen; Yufei Zhu; Xinhuo Huang; Xiaojun Yang; Zhouzheng Ren
Journal:  Anim Nutr       Date:  2021-11-17

8.  PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.